Buscar resultados de ensayos clínicos
Anaplastic Large Cell Lymphoma - 61 Studies Found
| Estado | Estudiar |
| Completed |
Nombre del estudio: Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma Condición: Large Cell Lymphoma Fecha: 2004-12-10 Intervenciones: Drug: SGN-30 |
| Completed |
Nombre del estudio: Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas Condición: Anaplastic Large Cell Lymphoma, ALK-Positive Fecha: 2015-04-03 Intervenciones: Drug: crizotinib |
| Withdrawn |
Nombre del estudio: MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma Condición: Lymphoma, Large-Cell Fecha: 2006-03-01 Intervenciones: Drug: MDX-060 |
| Active, not recruiting |
Nombre del estudio: Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Condición:
|
| Completed |
Nombre del estudio: A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma Condición:
Fecha: 2009-03-19 Intervenciones: Drug: brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion |
| Completed |
Nombre del estudio: Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma Condición: Lymphoma Fecha: 1999-11-01 Intervenciones: Biological: monoclonal antibody HeFi-1 |
| Recruiting |
Nombre del estudio: AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma Condición:
|
| Active, not recruiting |
Nombre del estudio: ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Condición:
Intervenciones: |
| Recruiting |
Nombre del estudio: Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) Condición: Lymphoma Fecha: 2014-06-11 Intervenciones: Drug: Brentuximab Vedotin Starting dose: 1.2 mg/kg by vein on Day 1 for the first 2, 21 day cycles. Dose |
| Completed |
Nombre del estudio: Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas Condición: Non-Hodgkin Lymphoma Fecha: 2014-10-05 Intervenciones: Drug: Brentuximab vedotin Brentuximab vedotin must not be administered as an IV push or bolus. It must b |